CN106174556A - A kind of soybean ovolecithin capsule - Google Patents
A kind of soybean ovolecithin capsule Download PDFInfo
- Publication number
- CN106174556A CN106174556A CN201610508882.1A CN201610508882A CN106174556A CN 106174556 A CN106174556 A CN 106174556A CN 201610508882 A CN201610508882 A CN 201610508882A CN 106174556 A CN106174556 A CN 106174556A
- Authority
- CN
- China
- Prior art keywords
- soybean
- glue
- capsule
- phospholipid
- lecithin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 14
- 235000010469 Glycine max Nutrition 0.000 title claims abstract description 12
- 244000068988 Glycine max Species 0.000 title claims abstract description 11
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 29
- 229940067606 lecithin Drugs 0.000 claims abstract description 29
- 235000010445 lecithin Nutrition 0.000 claims abstract description 29
- 239000000787 lecithin Substances 0.000 claims abstract description 29
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 21
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims abstract description 19
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000008347 soybean phospholipid Substances 0.000 claims abstract description 14
- 239000000843 powder Substances 0.000 claims abstract description 12
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000012424 soybean oil Nutrition 0.000 claims abstract description 8
- 239000003549 soybean oil Substances 0.000 claims abstract description 8
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 8
- 229940046009 vitamin E Drugs 0.000 claims abstract description 8
- 239000011709 vitamin E Substances 0.000 claims abstract description 8
- 239000003292 glue Substances 0.000 claims description 22
- 239000007901 soft capsule Substances 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 239000007903 gelatin capsule Substances 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 229940083466 soybean lecithin Drugs 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 4
- 230000001804 emulsifying effect Effects 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 238000007664 blowing Methods 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 238000009413 insulation Methods 0.000 claims description 3
- 235000015110 jellies Nutrition 0.000 claims description 3
- 239000008274 jelly Substances 0.000 claims description 3
- 239000000155 melt Substances 0.000 claims description 3
- 239000008188 pellet Substances 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 238000004513 sizing Methods 0.000 claims description 3
- 230000003068 static effect Effects 0.000 claims description 3
- 238000003860 storage Methods 0.000 claims description 3
- 238000010792 warming Methods 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 abstract description 8
- 239000008280 blood Substances 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 8
- 230000003064 anti-oxidating effect Effects 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 22
- 239000000047 product Substances 0.000 description 9
- 235000012000 cholesterol Nutrition 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 7
- 208000031226 Hyperlipidaemia Diseases 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 206010022998 Irritability Diseases 0.000 description 4
- 201000001883 cholelithiasis Diseases 0.000 description 4
- 235000021590 normal diet Nutrition 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 108010023302 HDL Cholesterol Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 210000004958 brain cell Anatomy 0.000 description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 3
- 229960001231 choline Drugs 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 235000013350 formula milk Nutrition 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000000050 nutritive effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010012665 Diabetic gangrene Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- LEMUFSYUPGXXCM-JNEQYSBXSA-N caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000001904 diabetogenic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000004203 pancreatic function Effects 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 108700022737 rat Fat1 Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The open a kind of soybean ovolecithin capsule of the present invention, its content contains soybean phospholipid, soybean oil, vitamin E, soybean phospholipid is combined by concentrated phosphatide, powder phospholipid, lecithin, formula for a product is reasonable, functional component highlights, and proves have good antioxidation, the effect of auxiliary blood fat reducing through human feeding trial.
Description
Technical field
The present invention relates to a kind of health food, a kind of soybean ovolecithin capsule.
Background technology
Phospholipid is the basis of human body cell (cell membrane, nuclear membrane, plastid film), and has weight to nerve, reproduction, hormone etc.
It is related to that there is very high nutritive value and medical value.Modern's rhythm of life is nervous, and phospholipid nutritive runs off in a large number, therefore mends
Charging whole phospholipid is imperative for modern.In view of soy phospholipids health product are a kind of functional health food,
Although not taking effect immediately, but having and write comprehensive, long-range, stable effect, do not have again side effects of pharmaceutical drugs simultaneously, physicians are also
Start the positive role paying attention to lecithin in terms of prevention disease generation.
Summary of the invention
The present invention provides a kind of soybean ovolecithin capsule, and it contains soybean phospholipid, soybean oil, vitamin E, soybean phospholipid by
Concentrated phosphatide, powder phospholipid, lecithin combine, and have formula for a product reasonable, and the feature that functional component is prominent can be long-term
Take, have no side effect, well solve the hyperlipidemia problem of old people.
A kind of soybean ovolecithin capsule, its product content thing containing soybean phospholipid 500-600 part, soybean oil 150-240 part,
Vitamin E 1.2-4.5 part, its preparation method is:
A. feed liquid configuration: soybean phospholipid is first dissolved in soybean oil, then the addition of load weighted vitamin E is stirred, will stir
The raw material mixed is sufficiently mixed in reactor, warming while stirring, controls the temperature of material less than 50 DEG C.Stir 6～7 hours
After, after standing emulsifying 8 hours, by about 35～40 DEG C of heat preservation for standby use of 200 mesh net filtration blowing；
B. glue configuration: add in reactor by water and glycerol, after change glue tank is heated to 60 DEG C, by pouring into of jelly powder
In glue tank, closing charging aperture, stirring is heated up to 70～80 DEG C.Vacuum pump switch, removed under reduced pressure is opened after gelatin melts completely
The bubble of glue, keeping vacuum is-0.06～-0.08MPa, and the time of evacuation is 40～50 minutes.By glue by double
After layer 80 eye mesh screen filters, put about 55 DEG C insulations in storage glue tank standby；
C. pelleting: receive on pellet press by feed liquid and glue, carries out pelleting.Proceed to the soft capsule suppressed rotate sizing rotating cage
In be dried.Require that temperature controls at 18～26 DEG C, humidity 30%～40%, 6-18 hour time；
D. wash ball: forwarded to wash by stereotyped soft capsule between ball and pour in soft capsule washing machine, be limited with interior bucket 2/3, add food
With ethanol (95%), open soft capsule washing machine switch and make it run up at interior bucket, repeatedly clean soft gelatin capsule, until ball surface oil-free
Sense；
E. being dried: washed soft gelatin capsule is transferred to clean dried indoor, static dry, temperature controls at 20～26 DEG C, humidity control
System is 30%～64%；Detecting moisture with moisture teller, rubber moisture receives ball 9%～14%, obtains qualified soybean lecithin
Capsule.
Soybean phospholipid in content is that concentrated phosphatide accounts for 30-50%, powder phospholipid accounts for 20-40%, lecithin accounts for 10-50%.
According to the regulation of People's Republic of China's industry standard phospholipid general technical specifications (SB/T 10206), phospholipid root
It is divided into according to product manufacture and product characteristics: concentrated phosphatide, powdered phospholipid and lecithin three class.
Concentrated phosphatide: hydrated phospholipid is make mould shape or thick product through the operation such as vacuum dehydration, concentration.
Powdered phospholipid: concentrated phosphatide through defat, separate, the operation such as be dried and the powder granular products made.
Lecithin: concentrated phosphatide or powdered phospholipid extract through ethanol, separate, the operation such as be dried and prepare with phosphatidylcholine
It it is main gelled product.
Concentrated phosphatide quality index:
Powder phospholipid quality index:
Lecithin quality index:
Soybean lecithin is described as " threeth nutrient " arranged side by side with protein, vitamin.But, really understand soybean lecithin
People little, lecithin is at " the noble's food " that China is also that a few peoples enjoy.And in developed country, lecithin becomes
The most universal nutraceutical.It has been said that American cooks also has used lecithin, the rice grain cooked is full, sparkling and crystal-clear to be picked
Thoroughly, fragrance overflows people.
Choline in phospholipid has affinity to fat, if internal choline is not enough, then can affect lipid metabolism, causes fat to exist
Liver inner accumulated, forming fatty liver even can inflammation swelling.Lecithin not only can prevent fatty liver, moreover it is possible to promotes liver cell regeneration,
Meanwhile, phospholipid can reduce serum cholesterol content, prevents liver cirrhosis and contributes to the recovery of liver function.
Lecithin deficiency can make pancreas function decline, it is impossible to secretes sufficient insulin, it is impossible to effectively by blood
Glucose transport is in cell, and this is to lead one of diabetogenic fundamental cause.As eaten the lecithin of more than 20 grams every day, then
The recovery of diabetes is the most significant.A lot of patients even can insulin injection again.Particularly to diabetic gangrene and
The complication patients such as arteriosclerosis are more effectively.
The effect that lecithin has emulsifying, cuts grease, can promote blood circulation, improves serum lipids, removes peroxidating
Thing, makes Blood Cholesterol and neutral fat content reduce, and reduces fatty in the holdup time of blood vessel, promotes atherosis
The dissipation of speckle, prevents the blood vessel internal membrane damage caused by cholesterol.Take lecithin hyperlipidemia and hypercholesterolemia are had significantly
Effect, thus can prevent and treat arteriosclerosis.
Under normal circumstances, containing substantial amounts of lecithin in the amniotic fluid in anemia of pregnant woman's body.Human body brain cell there are about 15,000,000,000, its
In 70% formed in parent.In order to promote fetal brain cell energy healthy development, anemia of pregnant woman supplements enough lecithin and is
Critically important.Infant is that brain is formed and grows most critical period period, and lecithin can promote that cerebral nervous system holds with brain
Long-pending growth, growth.Therefore FDA (FDA) regulation must add lecithin in baby milk.
It is contained within many toxin normal human, particularly in intestinal, when these content of toxins are too high, will be along with
Blood circulation is deposited on skin, thus forms mottle or comedo.Lecithin is exactly a kind of natural antidote, and it can divide
Solve internal too much toxin, and excrete through the process of liver and kidney, when internal toxin is reduced to finite concentration, face
On speckle and comedo will slowly disappear.Lecithin also has certain hydrophilic, and has the function increasing haemachrome, as
Really take a certain amount of lecithin every day, just can provide sufficient moisture and oxygen for skin, make skin become smooth soft and moist.
With age, memory can go down people, and its reason and acetyl choline content deficiency have certain relation.Acetyl gallbladder
The compound that alkali is required when being the transmission of nervous system information, people's brain-capacity is directly absorbed phospholipid and choline from blood, and is quickly turned
Turn to acetylcholine.The long-term lecithin that supplements can slow down the process of hypomnesis, prevents or postpone the generation of senile dementia.
Internal too much cholesterol can precipitate, thus forms cholelithiasis, and cholelithiasis 90% is made up of cholesterol.Gallbladder
Main component in juice is lecithin, and in addition with moisture, cholesterol, mineral and pigment etc., lecithin can be by unnecessary
Cholesterol decomposition, digest and absorb, so that the cholesterol in bile keeps liquid.If every day absorbs a certain amount of ovum phosphorus
Fat can be effectively prevented the formation of cholelithiasis, and established cholelithiasis also can play the effect dissolved.
Social competition is growing more intense, people be in for a long time anxiety environment and all pressure under, often suffer from anxiety, irritability,
The diseases, i.e. autonomic nervous dysfunction, commonly referred to neurasthenia such as irritability, insomnia, tinnitus.Often supplement lecithin, brain god can be made
Nutritional supplementation is obtained through in time, the duty kept fit, beneficially allaying tiredness, intensify brain cell, improve because of nervous
And the symptoms such as the irritability caused, irritability, insomnia.
Detailed description of the invention
Describe technical scheme in detail below in conjunction with embodiment and experimental example, but protection domain is not limited by this.
Embodiment 1
A kind of soybean ovolecithin capsule, its product content thing contains soybean phospholipid 560 parts, soybean oil 160 parts, vitamin E 3
Part, in soybean phospholipid, concentrated phosphatide accounts for 40%, powder phospholipid accounts for 35%, lecithin accounts for 25%.
Its preparation method is:
A. feed liquid configuration: lecithin, powder phospholipid, concentrated phosphatide are successively dissolved in soybean oil, then by load weighted vitamin
E addition stirs, and is sufficiently mixed by the raw material being stirred, warming while stirring in reactor, and the temperature controlling material is little
In 50 DEG C.After stirring 6 hours, after standing emulsifying 8 hours, by about 38 DEG C of heat preservation for standby use of 200 mesh net filtration blowing；
B. glue configuration: add in reactor by water and glycerol, after change glue tank is heated to 60 DEG C, by pouring into of jelly powder
In glue tank, closing charging aperture, stirring is heated up to 72 DEG C.Vacuum pump switch, removed under reduced pressure glue is opened after gelatin melts completely
Bubble, keep vacuum be-0.06～-0.08MPa, the time of evacuation is 42 minutes.By glue by double-deck 80 mesh sieves
After net filtration, put about 55 DEG C insulations in storage glue tank standby；
C. pelleting: receive on pellet press by feed liquid and glue, carries out pelleting.Proceed to the soft capsule suppressed rotate sizing rotating cage
In be dried.Require that temperature controls at 18～26 DEG C, humidity 30%～40%, 10 hours time；
D. wash ball: forwarded to wash by stereotyped soft capsule between ball and pour in soft capsule washing machine, be limited with interior bucket 2/3, add food
With ethanol (95%), open soft capsule washing machine switch and make it run up at interior bucket, repeatedly clean soft gelatin capsule, until ball surface oil-free
Sense；
E. being dried: washed soft gelatin capsule is transferred to clean dried indoor, static dry, temperature controls at 20～26 DEG C, humidity control
System is 30%～64%；Detecting moisture with moisture teller, rubber moisture receives ball 9%～14%, obtains qualified soybean lecithin
Capsule.
Zoopery
Materials and methods
1 material
The soybean ovolecithin capsule of 1.1 sample copy invention preparations.
1.2 high lipid food 78.8 g normal feedstuff add cholesterol 1 g, cholate 0.2 g, Adeps Sus domestica 10g, yolk powder 10
G is formulated.
1.3 laboratory animal SD rats, male, body weight 16o～220g, Chinese Academy of Sciences's Shanghai Experimental Animal Center carry
Supply.
2 methods require to carry out according to Ministry of Public Health " function of health food assessment process and the method for inspection ".Take rat 50
Only, after normal diet feed 5d, weigh, take tail blood, survey serum total cholesterol (TC), triglyceride (TG), high density lipoprotein level
White cholesterol (III) LC) basic value, then according to T DEG C of level, rat is randomly divided into 5 groups, often group 10, respectively Semen sojae atricolor
The basic, normal, high 3 dosage groups of phospholipid, hyperlipidemia model group and normal diet group.Tested material is given, except general in gavage mode (1Omg/kg)
Outside logical feedstuff group, the equal feed high lipid food of each group.After feeding 30d continuously, weigh, take the big every blood lipids index of rathole hematometry.
The 3 all data of statistical analysis represent with ± s, and statistical analysis uses SPSS11.0 statistical software.Many group mean ratios
Relatively using one factor analysis of variance (ANOVA) and t inspection, P < 0.05 represents that difference has statistical significance.
Result
The impact on rat body weight of 1 soybean ovolecithin capsule
Experiment respectively organizes rat body weight when starting does not has notable difference；Normal diet group and hyperlipidemia model group and each dose at the end of experiment
Amount group is compared, and weightening finish is decreased obviously, and difference has statistical significance (P < 0.05).Body after laboratory animal feed high lipid food is described
Weight substantially increases, and the weight of animals is had no significant effect by tested material soybean phospholipid.It is shown in Table l.
The impact on rat fat index of 2 soybean ovolecithin capsules
Before and after feed tested material, Serum TC, TG and HDL-C content are as shown in table 2～table 4.Before experiment, each group blood lipids index is equal
No significant difference；Experiment end hyperlipidemia model group compared with normal diet group, TC and TG significantly raised (P < 0.05), HDL-C content
Front and back change inconspicuous, illustrate that hyperlipemia model is successfully established；Experiment end sample each dosage group compared with model control group, TC
(P < 0.05) all it is decreased obviously with TG, although HDL-C content has, with each dosage group, the trend gradually risen, but relatively hyperlipidemia model group
And there was no significant difference；And from three big blood lipids index on pretreatment after variable quantity from the point of view of, there is certain dose-effect relationship,
Prompting soybean phospholipid has auxiliary lipid-lowering function.
Being described in detail the present invention above, the explanation of above example is only intended to help and understands the present invention.This area
It is to be appreciated by one skilled in the art that technical scheme can be changed, retouch or equivalent, and do not take off
From the spirit and scope of technical solution of the present invention, it all should belong in the middle of the claims of the present invention.
Claims (2)
1. a soybean ovolecithin capsule, is characterized in that product content thing is containing soybean phospholipid 500-600 part, soybean oil 150-240
Part, vitamin E 1.2-4.5 part, its preparation method is:
A feed liquid configures: be first dissolved in soybean oil by soybean phospholipid, then the addition of load weighted vitamin E is stirred, will stirring
Good raw material is sufficiently mixed in reactor, warming while stirring, controls the temperature of material less than 50 DEG C；
After stirring 6～7 hours, after standing emulsifying 8 hours, by about 35～40 DEG C of heat preservation for standby use of 200 mesh net filtration blowing；
B glue configures: add in reactor by water and glycerol, after change glue tank is heated to 60 DEG C, by jelly powder pouring into glue
In tank, closing charging aperture, stirring is heated up to 70～80 DEG C；
After gelatin melts completely, open vacuum pump switch, the bubble of removed under reduced pressure glue, keep vacuum be-0.06～-
0.08MPa, the time of evacuation is 40～50 minutes, by glue by double-deck 80 eye mesh screens filter after, put storage glue tank in 55 DEG C
Left and right insulation is standby；
C pelleting: receive on pellet press by feed liquid and glue, carries out pelleting, proceeds to the soft capsule suppressed rotate sizing rotating cage
In be dried, it is desirable to temperature controls at 18～26 DEG C, humidity 30%～40%, 6-18 hour time；
D washes ball: is forwarded to wash by stereotyped soft capsule between ball and pours in soft capsule washing machine, is limited with interior bucket 2/3, adds edible
Ethanol (95%), opens soft capsule washing machine switch and makes it run up at interior bucket, repeatedly clean soft gelatin capsule, until the oil-free sense of ball surface；
E is dried: washed soft gelatin capsule is transferred to clean dried indoor, and static dry, temperature controls at 20～26 DEG C, humid control
30%～64%；Detecting moisture with moisture teller, rubber moisture receives ball 9%～14%, obtains qualified soybean lecithin glue
Capsule.
The most according to claim 1, the soybean phospholipid in content is characterized by that concentrated phosphatide accounts for 30-50%, powder phospholipid accounts for
20-40%, lecithin account for 10-50%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610508882.1A CN106174556A (en) | 2016-07-02 | 2016-07-02 | A kind of soybean ovolecithin capsule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610508882.1A CN106174556A (en) | 2016-07-02 | 2016-07-02 | A kind of soybean ovolecithin capsule |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106174556A true CN106174556A (en) | 2016-12-07 |
Family
ID=57462857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610508882.1A Withdrawn CN106174556A (en) | 2016-07-02 | 2016-07-02 | A kind of soybean ovolecithin capsule |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106174556A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107519477A (en) * | 2017-06-26 | 2017-12-29 | 郑相国 | Chinese patent drug with healthcare function |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101016312A (en) * | 2007-02-07 | 2007-08-15 | 崔澎 | Method of preparing powder phosphatide and lecithin for medicine and injection from soybean oil residue |
| CN101186621A (en) * | 2007-12-14 | 2008-05-28 | 华南理工大学 | Membrane process production method for soybean high purity liquid phosphatide and powdery phosphatide |
| CN101611760A (en) * | 2008-06-26 | 2009-12-30 | 威海清华紫光科技开发有限公司 | The extraction of soybean lecithin and the production method of series of products thereof |
| CN103191176A (en) * | 2013-04-03 | 2013-07-10 | 上海春芝堂生物制品有限公司 | Soybean phospholipids soft capsule and preparation method thereof |
-
2016
- 2016-07-02 CN CN201610508882.1A patent/CN106174556A/en not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101016312A (en) * | 2007-02-07 | 2007-08-15 | 崔澎 | Method of preparing powder phosphatide and lecithin for medicine and injection from soybean oil residue |
| CN101186621A (en) * | 2007-12-14 | 2008-05-28 | 华南理工大学 | Membrane process production method for soybean high purity liquid phosphatide and powdery phosphatide |
| CN101611760A (en) * | 2008-06-26 | 2009-12-30 | 威海清华紫光科技开发有限公司 | The extraction of soybean lecithin and the production method of series of products thereof |
| CN103191176A (en) * | 2013-04-03 | 2013-07-10 | 上海春芝堂生物制品有限公司 | Soybean phospholipids soft capsule and preparation method thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107519477A (en) * | 2017-06-26 | 2017-12-29 | 郑相国 | Chinese patent drug with healthcare function |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105613789B (en) | High-fat high-dietary-fiber composite animal and plant powdered oil and fat, and preparation method and application thereof | |
| CN101366451B (en) | Feedstuff additive for improving oil and fat assimilation utilization ratio and preparation method thereof | |
| CN107836552A (en) | A kind of DHA gel candies and preparation method thereof | |
| CN103156198A (en) | Fish oil soft capsules and preparation method thereof | |
| CN103315299A (en) | Health-care food with function of enhancing immunity and memory | |
| CN104783028A (en) | A probiotic and a processing method thereof | |
| CN104256610B (en) | A kind of health composition of auxiliary antilipemic and soft capsule | |
| CN107212256A (en) | A kind of meal replacement powder with function of blood sugar reduction and preparation method thereof | |
| CN103141845B (en) | Soft phytosterol capsule and method for preparing same | |
| CN103494207B (en) | Method for preparing pure peony seed essential oil soft capsules | |
| CN103006709B (en) | Bee-pollen buccal tablet for preventing and treating alcoholic fatty liver | |
| CN106174556A (en) | A kind of soybean ovolecithin capsule | |
| CN105166901B (en) | A kind of dialysis patient alimentation composition | |
| CN101438780B (en) | Formula of xylitol sweet good and method for producing the same | |
| CN100402052C (en) | Blood fat-reducing medicine and its preparation method | |
| CN103690821B (en) | A kind of auxiliary antilipemic compositions | |
| CN109645124A (en) | A kind of nutrient powder and preparation method thereof of suitable patients with diabetes mellitus | |
| CN106620090A (en) | Composition for reducing blood glucose, and preparation method of composition | |
| CN106943487A (en) | A kind of composition containing rosemary, preparation method and applications | |
| CN103637212B (en) | Tube feeding clinical nourishment with blood fat reducing effect and preparation method thereof | |
| CN113749181A (en) | Valley-free soft lozenge formula for cats and preparation method thereof | |
| CN102204867B (en) | Preparation method of liposome with functions of fat reduction and calcium supplement | |
| CN110050847A (en) | A kind of high fat diet and fatty acid mixed edible plant blend oil | |
| CN1861061A (en) | Medicine for treating or preventing newborn hemorrhagic disease | |
| CN110122747A (en) | A kind of generation meal steamed bun and preparation method thereof based on sugared balance mechanism |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20161207 |
|
| WW01 | Invention patent application withdrawn after publication |